A 38-year-old woman with bipolar disorder type I has been on lithium 900 mg daily for 6 months with good mood stabilization. She now presents with polyuria (3 L/day), polydipsia, and serum sodium 148 mEq/L. Serum lithium level is 0.8 mEq/L (therapeutic range). Urine osmolality is 180 mOsm/kg. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis The patient has classic features of **lithium-induced nephrogenic diabetes insipidus (NDI)**: - Polyuria (3 L/day) and polydipsia - Hypernatremia (Na⁺ 148 mEq/L) - Low urine osmolality (180 mOsm/kg) despite elevated serum osmolality - Therapeutic lithium level (0.8 mEq/L) — toxicity is NOT the cause ## Pathophysiology **Key Point:** Lithium causes NDI by downregulating and blocking **aquaporin-2 (AQP2) water channels** in the collecting duct principal cells, impairing ADH (vasopressin)-mediated water reabsorption. This occurs in ~20–40% of patients on chronic lithium therapy and can be **partially irreversible** even after lithium discontinuation (KD Tripathi, *Essentials of Medical Pharmacology*, 8th ed.). ## Why Desmopressin + Continuing Lithium Is the Best Next Step **High-Yield:** The verifier suggested switching to valproate, but this is NOT the most appropriate *next step* for the following reasons: 1. **Lithium is providing good mood stabilization** — abrupt or rapid discontinuation risks bipolar relapse, which carries significant morbidity (Harrison's Principles of Internal Medicine, 21st ed.) 2. **Desmopressin (DDAVP)** is a synthetic V2-receptor agonist that can partially overcome the AQP2 defect in lithium-NDI, reducing polyuria and correcting hypernatremia 3. **The lithium level is therapeutic (0.8 mEq/L)** — there is no indication to increase the dose (Option A is wrong and dangerous) 4. **Switching to valproate** is a valid *eventual* consideration if NDI is refractory, but it is not the immediate next step when desmopressin has not yet been tried 5. **Water deprivation test (Option D)** is **contraindicated** in a patient who is already hypernatremic (Na⁺ 148 mEq/L) — the diagnosis is clinically established and further dehydration is harmful ### Concurrent Management - Continue lithium at current dose with close monitoring of serum Na⁺ and lithium levels - Ensure adequate free water intake - Consider amiloride (blocks lithium entry into principal cells) as an adjunct if desmopressin response is suboptimal - Educate patient on fluid and salt intake ### When to Consider Lithium Discontinuation / Switch to Valproate **Clinical Pearl:** Lithium discontinuation and switch to an alternative mood stabilizer (e.g., valproate, lamotrigine) is indicated only if: - NDI is severe and refractory to desmopressin and amiloride - Progressive renal insufficiency develops (eGFR <30 mL/min) - The patient's psychiatric condition can be equally well managed with an alternative agent ## Differential Diagnosis of Polyuria | Feature | Lithium NDI | Central DI | Psychogenic Polydipsia | |---------|-----------|-----------|------------------------| | Urine osmolality | Low (<300) | Low (<300) | Low (<300) | | Response to desmopressin | Partial/minimal | Dramatic (>50% rise) | No | | Serum Na⁺ | High/normal | High | Low/normal | | Mechanism | AQP2 blockade | ADH deficiency | Primary polydipsia | **Warning:** Do NOT perform water deprivation test in a hypernatremic patient — it worsens dehydration and hypernatremia. The clinical and biochemical picture already confirms NDI in this context. *Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Harrison's Principles of Internal Medicine, 21st ed.*